Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+lymphomas.

被引：1
|
作者：
Schuster, Stephen J.
Svoboda, Jakub
Nasta, Sunita
Porter, David L.
Mato, Anthony
Shah, Gaurav D.
Landsburg, Daniel Jeffrey
Chong, Elise A.
Lacey, Simon F.
Melenhorst, Jan J.
Chew, Anne
Hasskarl, Jens
Shah, Nirav Niranjan
Wasik, Mariusz A.
Marcucci, Katherine
Zheng, Zhaohui
Levine, Bruce
June, Carl H.
机构：
[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA
[3] Univ Penn Hlth Syst, Philadelphia, PA USA
[4] Novartis Pharmaceut, Florham Pk, NJ USA
[5] Novartis, Basel, Switzerland
[6] Univ Penn, Translat Res Program, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8516
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+Lymphomas
    Schuster, Stephen J.
    Svoboda, Jakub
    Nasta, Sunita Dwivedy
    Porter, David L.
    Chong, Elise A.
    Mahnke, Yolanda
    Lacey, Simon F.
    Melenhorst, J. Joseph
    Chew, Anne
    Shah, Gaurav
    Hasskarl, Jens
    Litchman, Manuel
    Wasik, Mariusz A.
    Landsburg, Daniel J.
    Mato, Anthony R.
    Garfall, Alfred L.
    Frey, Noelle V.
    Marcucci, Katherine T.
    Shea, Joanne
    McConville, Holly
    Zheng, Zhaohui
    Levine, Bruce L.
    June, Carl H.
    BLOOD, 2014, 124 (21)
  • [2] CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS DIRECTED AGAINST CD19 (CTL019) INDUCE CLINICAL RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY CD19+LYMPHOMAS
    Levine, B.
    Svoboda, J.
    Nasta, S. D.
    Porter, D.
    Chong, E.
    Lacey, S.
    Mahnke, Y.
    Melenhorst, J.
    Chew, A.
    Shah, G.
    Hasskar, J.
    Wasik, M.
    Landsburg, D.
    Mato, A.
    Garfall, A.
    Frey, N.
    Shaw, P.
    Marcucci, K.
    Shea, J.
    McConville, H.
    Manvar, N.
    O'Rourke, M.
    Lamontagne, A.
    Bersenev, A.
    Zheng, Z.
    Schuster, S.
    June, C.
    CYTOTHERAPY, 2015, 17 (06) : S13 - S13
  • [3] Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+Lymphomas
    Schuster, Stephen J.
    Svoboda, Jakub
    Nasta, Sunita Dwivedy
    Porter, David L.
    Chong, Elise A.
    Landsburg, Daniel J.
    Mato, Anthony R.
    Lacey, Simon F.
    Melenhorst, Jan J.
    Chew, Anne
    Hasskarl, Jens
    Shah, Gaurav D.
    Wasik, Mariusz A.
    Marcucci, Katherine T.
    Zheng, Zhaohui
    Levine, Bruce L.
    June, Carl H.
    BLOOD, 2015, 126 (23)
  • [4] Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL
    Porter, David L.
    Kalos, Michael
    Frey, Noelle V.
    Grupp, Stephan A.
    Loren, Alison W.
    Jemision, Christina
    Gilmore, Joan
    McConville, Holly
    Capobianchi, James
    Lledo, Lester
    Chew, Anne
    Shen, Angela
    Wood, Patricia A.
    Litchman, Manuel
    Zheng, Zhaohui
    Levine, Bruce L.
    June, Carl H.
    BLOOD, 2013, 122 (21)
  • [5] Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL
    Porter, David L.
    Frey, Noelle V.
    Melenhorst, J. Joseph
    Hwang, Wei-Ting
    Lacey, Simon F.
    Shaw, Pamela
    Chew, Anne
    Grupp, Stephan A.
    Capobianchi, James
    Gilmore, Joan
    Kalos, Michael
    Litchman, Manuel
    Lledo, Lester
    Loren, Alison Wakoff
    Mahnke, Yolanda
    Marcucci, Katherine T.
    McConville, Holly
    Shen, Angela
    Wood, Patricia A.
    Zheng, Zhaohui
    Levine, Bruce L.
    June, Carl H.
    BLOOD, 2014, 124 (21)
  • [6] Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy
    Chong, Elise A.
    Svoboda, Jakub
    Nasta, Sunita Dwivedy
    Porter, David L.
    Winchell, Nicole
    Landsburg, Daniel J.
    Mato, Anthony R.
    Lacey, Simon F.
    Melenhorst, Jan J.
    Chew, Anne
    Hasskarl, Jens
    Marcucci, Katherine T.
    Levine, Bruce L.
    June, Carl H.
    Schuster, Stephen J.
    BLOOD, 2016, 128 (22)
  • [7] Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+Leukemia
    Mueller, Karen Thudium
    Chakraborty, Abhijit
    Wood, Patricia A.
    Awasthi, Rakesh
    Quintas-Cardama, Alfonso
    Han, Xia
    Maude, Shannon L.
    Grupp, Stephan A.
    Porter, David L.
    Frey, Noelle
    Marcucci, Katherine T.
    Levine, Bruce L.
    Melenhorst, Jan J.
    June, Carl H.
    Lacey, Simon F.
    BLOOD, 2016, 128 (22)
  • [8] Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019).
    Schuster, Stephen J.
    Svoboda, Jakub
    Nasta, Sunita
    Chong, Elise A.
    Porter, David L.
    Landsburg, Daniel Jeffrey
    Mato, Anthony R.
    Bhoj, Vijay G.
    Milone, Michael
    Lacey, Simon F.
    Strelec, Lauren E.
    Zhou, Alice Y.
    Melenhorst, Jan J.
    Chew, Anne
    Hasskarl, Jens
    Wasik, Mariusz A.
    Marcucci, Katherine
    Zheng, Zhaohui
    Levine, Bruce
    June, Carl H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Chimeric antigen receptor-modified T cells directed against CD19 in patients with relapsed or refractory CD19-positive B-cell lymphomas: interim analysis of a phase 1 study
    Ying, Zhitao
    Xiang, Xiaoyu
    Song, Yuqin
    Ding, Ning
    Lin, Yufu
    Zheng, Wen
    Wang, Xiaopei
    Lin, Ningjing
    Tu, Meifeng
    Xie, Yan
    Zhang, Chen
    Liu, Weiping
    Deng, Lijuan
    Liu, Yanling
    Yue, Yunqiang
    Yu, Xueyun
    Liu, Hanzhi
    Duan, Panpan
    Mamuti, Mierzhati
    Guo, Xiaokai
    Chen, Feng
    Wu, Xiaoyan
    Zhang, Junqing
    Zhang, Tingting
    Huang, Xue F.
    Jones, Lindsey
    Kang, Xi
    Chen, Si-Yi
    Zhu, Jun
    LANCET ONCOLOGY, 2017, 18 : S9 - S9
  • [10] Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)
    Grupp, Stephan A.
    Maude, Shannon L.
    Shaw, Pamela A.
    Aplenc, Richard
    Barrett, David M.
    Callahan, Colleen
    Lacey, Simon F.
    Levine, Bruce L.
    Melenhorst, J. Joseph
    Motley, Laura
    Rheingold, Susan R.
    Teachey, David T.
    Wood, Patricia A.
    Porter, David
    June, Carl H.
    BLOOD, 2015, 126 (23)
12345